Johnson & Johnson "very confident" in vaccine, eyes quick resolution

(Alliance News) - Johnson & Johnson remains "very confident" in its Covid-19 vaccine and hopeful ...

Alliance News 20 April, 2021 | 12:28PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Johnson & Johnson remains "very confident" in its Covid-19 vaccine and hopeful for a quick resolution from regulators over its status, a top executive said Tuesday.

"We remain very confident and very hopeful that the benefit-risk profile will play out," J&J Chief Financial Officer Joseph Wolk told CNBC.

The comments came ahead of a decision expected later Tuesday from Europe's drug regulator on the safety of the single-shot innoculation. 

US pandemic advisor Anthony Fauci said the US is likely to announce its decision by Friday.

Health authorities in the US on April 14 recommended a pause on the vaccine following six instances of severe blood clots out of nearly seven million Americans who received the vaccine.

The company hopes "very shortly ... perhaps as early as the end of this week, to have some resolution with how we are going to proceed," Wolk said.

When asked if the US decision to suspend the program hindered public confidence in vaccines, Wolk said "I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine."

The comments came as J&J released first quarter results.

An earnings press release did not elaborate on vaccine approval issues, but said the vaccine generated USD100 million in revenues in the US during the period. J&J is selling the vaccine at cost.

J&J has also encountered production problems at a Baltimore, Maryland factory managed by Emergent BioSolutions.

The US Food & Drug Administration has suspended production in the plant pending a review of the facility.

Wolk said J&J expects to be "in a position to meet our contract commitments, not just here in the US but across the globe" following the FDA review.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Johnson & Johnson 144.65 USD -0.08

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures